Application of stem cell-derived exosome in preparation of brain-targeted vector
By using stem cell-derived exosomes as carriers, targeted delivery of drugs and diagnostic reagents to the brain, the problem of difficult blood-brain barriers is solved, and the effectiveness of Alzheimer's disease treatment and diagnostic accuracy is significantly improved.
Patent Information
- Application Number
- CN202411007607.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art is difficult to cross the blood-brain barrier, making it difficult for drugs in Alzheimer's disease to reach the brain, reducing the therapeutic effect.
Use stem cell-derived exosomes as carriers to target the delivery of drugs, diagnostic reagents or substances that help improve memory and sleep to the brain, increasing or controlling the concentration of active ingredients in the brain, and enhancing the efficacy of drugs.
It significantly improves the concentration and efficacy of the drug in the brain, enhances the brain targeting of the drug, is conducive to the treatment of brain diseases, reduces side effects, and improves the accuracy and bioavailability of diagnosis.
Smart Images

Figure HDA0004963388450000011 
Figure HDA0004963388450000012 
Figure HDA0004963388450000013
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biological carrier targeted delivery, and in particular to the use of stem cell-derived exosomes in the preparation of brain-targeted carriers. Background Art
[0002] Alzheimer's Disease (AD) is a common neurodegenerative disease, which is mainly manifested by memory loss, cognitive decline and behavioral changes. It is the most common cause of senile dementia. With the aging of the global population, the incidence and prevalence of AD are increasing. The Aβ cascade hypothesis is the mainstream theory used to explain the pathogenesis of AD. The hypothesis points out that senile plaques formed by abnormal aggregation of Aβ (β-amyloid protein) in cells are the main driving factors leading to AD neurodegeneration and cognitive decline. Therefore, the clearance or degradation of Aβ is considered an important target for AD treatment.
[0003] Insulin-Degrading Enzyme (IDE) is a neutral zinc metallo-peptidase with a molecular weight of 110 kDa, which can degrade a variety of substrates with a common amyloid secondary protein structure, such as the Alzheimer's disease pathogenic protein β-amyloid protein (Amyloid-β, referred to as "Aβ"). However, the expression level of IDE is significantly reduced in the brains of AD patients and animal models. Studies have found that overexpression of IDE in neurons can significantly reduce the level of Aβ in the brain, delay or even completely prevent the formation of Aβ deposits and related cellular pathological changes, and improve cognitive impairment in AD model animals. However, like the challenges faced in the development of other drugs related to the treatment of brain diseases, IDE has difficulty crossing the blood-brain barrier, which limits its application in the treatment of AD.
[0004] Therefore, there is an urgent need to develop drug carriers with enhanced brain targeting to promote the development of drugs for the treatment of brain diseases and improve drug efficacy. Summary of the invention
[0005] The present invention aims to solve at least one of the technical problems existing in the prior art to a certain extent. To this end, the present invention provides the use of stem cell-derived exosomes in the preparation of brain-targeted carriers. The present invention unexpectedly found that stem cell-derived exosomes can be used as carriers to deliver active ingredients or medical devices such as drugs, diagnostic reagents, substances that assist in improving memory, substances that help improve sleep, etc. to the brain, thereby increasing or controlling the concentration of active ingredients in the brain, enhancing the efficacy of active ingredients, and facilitating the operation of medical devices in brain application scenarios.
[0006] It should be noted that the present invention is based on the inventor's discovery and understanding of the following problems:
[0007] In the occurrence and development of AD, the hippocampus of the brain is a particularly important area because it is closely related to memory and learning functions. Neuronal degeneration in the hippocampus is directly related to the decline in cognitive function in AD patients. In the occurrence and development of AD, the level of IDE in the hippocampus of the brain gradually decreases. Therefore, increasing the expression level of IDE in the brain may have clinical value in treating AD. The inventor's previous studies found that direct administration of IDE to experimental animals in vitro has a fast blood clearance rate, poor ability to target brain tissue and cells, and it is difficult to ensure efficient enzyme activity in vivo. The inventor further screened drug carriers with brain targeting and unexpectedly discovered that exosomes (Exosomes, referred to as "EXO" in this article) derived from bone marrow mesenchymal stem cells target the brain, and the EXO-IDE drug system constructed using them has significantly enhanced brain targeting.
[0008] Further experiments have shown that exosomes prepared from stem cells from other tissues (such as umbilical cord blood, bone marrow, embryo, placenta, fat, bone, cartilage, periodontal, synovial membrane, muscle, lung, liver, and pancreas), especially exosomes derived from mesenchymal stem cells, can target the delivery of active ingredients or nanoscale medical devices to the brain.
[0009] Therefore, in the first aspect of the present invention, the present invention proposes the use of stem cell-derived exosomes in the preparation of brain-targeted vectors. According to an embodiment of the present invention, the vector is used to deliver active ingredients or medical devices to the brain. The present invention unexpectedly discovered that exosomes derived from bone marrow mesenchymal stem cells can be used as carriers to deliver active ingredients or medical devices such as drugs, diagnostic agents, substances that assist in improving memory, substances that help improve sleep, etc. to the brain, thereby increasing or controlling the concentration of active ingredients in the brain, enhancing the efficacy of active ingredients, and facilitating the operation of medical devices in brain application scenarios.
[0010] In the second aspect of the present invention, the present invention proposes the use of stem cell-derived exosomes in the preparation of drugs, diagnostic reagents, health products or medical devices. According to an embodiment of the present invention, the drug is used to treat and / or prevent brain diseases, the diagnostic reagent is used to diagnose brain diseases, the health product is used to assist in improving memory or helping to improve sleep, and the application scenario of the medical device is the brain.
[0011] In the third aspect of the present invention, the present invention provides a delivery system. According to an embodiment of the present invention, the delivery system comprises: a carrier, an active ingredient or a medical device; the carrier comprises exosomes derived from stem cells, and the exosomes carry the active ingredient or the medical device; and the delivery system delivers the active ingredient or the medical device to the brain.
[0012] In a fourth aspect of the present invention, the present invention proposes the use of the aforementioned delivery system in the preparation of a drug, a diagnostic reagent, a health product or a medical device. According to an embodiment of the present invention, the drug is used to treat and / or prevent brain diseases, the diagnostic reagent is used to diagnose brain diseases, the health product is used to assist in improving memory or helping to improve sleep, and the application scenario of the medical device is the brain.
[0013] In a fifth aspect of the present invention, the present invention provides a method for preparing the aforementioned delivery system.
[0014] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] The above and / or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:
[0016] Figure 1 The figures are the characterization results of the morphology, particle concentration and size of the exosomes derived from mesenchymal stem cells in Example 1 of the present invention, wherein (A) is the result of transmission electron microscopy scanning; (B) is the result of the nanoparticle tracking analysis technology test;
[0017] Figure 2 This is a graph showing the loading rate investigation results of the EXO-IDE drug system constructed using different drug loading methods in Example 2 of the present invention, wherein "Electroporation" represents the electroporation method, "Extrusion" represents the extrusion method, and "Ultrasonic" represents the ultrasonic method;
[0018] Figure 3 The loading efficiency of the exosomes derived from mesenchymal stem cells on IDE in Example 3 of the present invention at different ultrasound times and different IDE and EXO feed ratios; wherein (A) is different ultrasound times; (B) is different IDE and EXO feed ratios;
[0019] Figure 4 The morphology and polydispersity coefficient characterization results of the EXO-IDE drug system in Example 4 of the present invention are shown in Figure 1, wherein (A) is the transmission electron microscope scanning result; (B) is the particle size analyzer inspection result;
[0020] Figure 5 The results of the brain targeting investigation of the EXO-IDE drug system in Example 5 of the present invention are shown in FIG. 1 , wherein (A) is the fluorescence imaging diagram of each experimental group; and (B) is the fluorescence quantitative statistical diagram of the experimental group. DETAILED DESCRIPTION
[0021] The embodiments of the present invention are described in detail below. The embodiments described below are exemplary and are only used to explain the present invention, and should not be understood as limiting the present invention.
[0022] It should be noted that the terms "first" and "second" are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. Further, in the description of the present invention, unless otherwise specified, the meaning of "plurality" is two or more.
[0023] The endpoints and any values of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values. For numerical ranges, the endpoint values of each range, the endpoint values of each range and the individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.
[0024] In this document, the terms “include” or “comprising” are open expressions, that is, including the contents specified in the present invention but not excluding other contents.
[0025] As used herein, the terms "optionally", "optional" or "optionally" generally mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
[0026] In this article, the term "Transmission Electron Microscope (TEM) is a high-resolution microscope that uses electron beams instead of light beams, which can provide higher magnification and resolution than traditional optical microscopes. It is usually used to observe nanoscale samples such as viruses, organelles, macromolecular complexes, etc.
[0027] As used herein, the term “Nanoparticle Tracking Analysis (NTA)” refers to a biophysical method used to analyze and characterize the size and concentration of nanoparticles.
[0028] In the embodiments of the present invention, transmission electron microscopy and nanoparticle tracking analysis technology are used to characterize the morphology, particle concentration and size of exosomes, respectively.
[0029] In this article, the term "exosomes (abbreviated as "EXO" in this article)" refers to a type of extracellular vesicles with a diameter of about 30 to 150 nm, which can be secreted by almost all types of cells (including cells in the central nervous system) under physiological or pathological conditions. Exosomes can directly act on receptor cells to play physiological roles such as intercellular substance transport and signal transduction. The differences in substances contained in exosomes from different cells mainly depend on the parent cells. Therefore, exosomes from different sources have different functions. Transmission electron microscopy can provide information about the morphology, size and structure of exosomes, which is crucial for studying the physical properties of exosomes and evaluating their potential as drug carriers. Nanoparticle tracking analysis technology can accurately measure the hydrodynamic diameter of exosomes, which helps to understand the size distribution and uniformity of exosomes; it can also quantitatively analyze the particle concentration of exosomes, providing basic data for studying their biological functions and potential applications.
[0030] In this article, the term "MSC-EXO" refers to exosomes derived from mesenchymal stem cells (MSCs), which, combined with the context, is equivalent to "exosomes derived from mesenchymal stem cells".
[0031] The present invention proposes the use of stem cell-derived exosomes in the preparation of brain-targeted vectors, in the preparation of drugs, diagnostic reagents, health products or medical devices, and also proposes a delivery system and its preparation method and application, which will be described in detail below.
[0032] Use of preparing brain targeting vector
[0033] The present invention proposes the use of stem cell-derived exosomes in the preparation of brain-targeted vectors. According to an embodiment of the present invention, the vector is used to deliver active ingredients or medical devices to the brain. The present invention unexpectedly discovered that exosomes derived from bone marrow mesenchymal stem cells can be used as carriers to deliver active ingredients or medical devices such as drugs, diagnostic reagents, substances that assist in improving memory, substances that help improve sleep, etc. to the brain, thereby increasing or controlling the concentration of active ingredients in the brain, enhancing the efficacy of active ingredients, and facilitating the operation of medical devices in brain application scenarios.
[0034] In this article, the term "brain-targeted carrier" is a special type of delivery system that can overcome the blood-brain barrier (Blood-Brain Barrier, BBB) and effectively deliver substances or nano-scale objects to the brain. For example, the carrier can deliver drug-active molecules to specific parts of the body (such as diseased tissues or cells) in the brain, thereby improving the therapeutic effect of drugs, reducing side effects, and optimizing drug dosages. For another example, the carrier can deliver diagnostic reagents to specific parts or targets in the body, such as diseased brain tissues or cells, to improve diagnostic accuracy, reduce non-specific reactions, reduce background noise, or improve the bioavailability of reagents. For another example, the carrier can carry nano-scale medical devices to the brain, which is beneficial for them to play a role in the brain.
[0035] According to an embodiment of the present invention, the stem cells are derived from, including but not limited to, umbilical cord, bone marrow, embryo, placenta, fat, bone, cartilage, periodontium, synovium, muscle, lung, liver, and pancreas.
[0036] It should be specially noted that, in the present invention, when stem cells are derived from human umbilical cord, embryo or placenta, the human umbilical cord, embryo or placenta referred to is within 14 days of fertilization without in vivo development.
[0037] According to an embodiment of the present invention, the stem cells are mesenchymal stem cells, thereby further improving the brain targeting of the vector.
[0038] According to an embodiment of the present invention, the stem cells include but are not limited to: umbilical cord mesenchymal stem cells, bone marrow mesenchymal stem cells, adipose mesenchymal stem cells, dental pulp mesenchymal stem cells, placental mesenchymal stem cells, amniotic mesenchymal stem cells, synovial mesenchymal stem cells, and thymus mesenchymal stem cells.
[0039] It should be noted that, in the present invention, the above-mentioned mesenchymal stem cells can usually be obtained commercially or by methods known in the art. The purchase or acquisition of the above-mentioned mesenchymal stem cells, especially human umbilical cord mesenchymal stem cells, bone marrow mesenchymal stem cells (hBMSCs), placental mesenchymal stem cells, and amniotic mesenchymal stem cells should be carried out in compliance with local laws and regulations, including cell therapy, import and export of biological materials, ethics and privacy protection. When the exosomes described in the present invention are obtained from umbilical cord mesenchymal stem cells, bone marrow mesenchymal stem cells, placental mesenchymal stem cells, and amniotic mesenchymal stem cells, these stem cells should also be within 14 days of fertilization without in vivo development.
[0040] According to an embodiment of the present invention, the stem cells are derived from animals including but not limited to: mice, rats, rabbits, dogs, pigs, and primates.
[0041] In some optional embodiments of the present invention, the primate is a non-human primate.
[0042] According to an embodiment of the present invention, the stem cells are mouse bone marrow mesenchymal stem cells. According to an embodiment of the present invention, a delivery system (such as the EXO-IDE drug system) constructed using exosomes obtained from mouse bone marrow mesenchymal stem cell cultures has significantly enhanced brain targeting.
[0043] According to an embodiment of the present invention, the brain is the cerebrum.
[0044] According to an embodiment of the present invention, the active ingredients include but are not limited to: active pharmaceutical ingredients and other biological molecules.
[0045] As used herein, the term "active ingredient" refers to a substance with biological activity that can have an effect on an organism, including treating or preventing a disease, or improving certain functions of an organism.
[0046] As used herein, the term "active pharmaceutical ingredient (API)" refers to any substance or mixture of substances used in the manufacture of pharmaceuticals that has pharmacological activity or other direct effects in the diagnosis, treatment, symptom relief, management or prevention of diseases, or can affect the function or structure of the body.
[0047] As used herein, the term "other biomolecules" includes substances having biological activity other than the pharmaceutically active ingredient.
[0048] In some specific embodiments of the present invention, the pharmaceutically active ingredient includes, but is not limited to, at least one of a compound, a polypeptide, a protein, a nucleic acid, and a polysaccharide.
[0049] According to an embodiment of the present invention, the protein is IDE. The exosomes derived from bone marrow mesenchymal stem cells according to an embodiment of the present invention can be used as carriers to deliver IDE protein to the brain in a targeted manner. Thus, the local concentration of IDE in brain neurons is increased, the level of Aβ in the brain is further reduced, and the formation of Aβ deposition and related cell pathological changes are delayed or prevented.
[0050] According to an embodiment of the present invention, the other biological molecules include but are not limited to: at least one of a diagnostic reagent, a substance that assists in improving memory, and a substance that helps improve sleep.
[0051] In some specific embodiments of the present invention, the diagnostic reagent includes, but is not limited to, at least one of a biomarker, an antibody, an enzyme, a nucleic acid probe, and an imaging agent.
[0052] Exemplarily, the biomarker can be a protein, gene, metabolite or other molecule, including but not limited to: β-amyloid protein, Tau protein, neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), S100B protein, myelin basic protein (MBP), gene markers (such as APOEε4 allele), metabolite markers, microRNA (miRNA) markers, long non-coding RNA (lncRNA) markers.
[0053] According to an embodiment of the present invention, exosomes derived from bone marrow mesenchymal stem cells can help the above substances penetrate the blood-brain barrier, enter the brain, and play the expected diagnostic role.
[0054] In some specific embodiments of the present invention, the substance that assists in improving memory includes, but is not limited to, at least one of folic acid, DHA, calcium, magnesium, zinc, and vitamin B.
[0055] In some specific embodiments of the present invention, the substance that helps improve sleep includes, but is not limited to, at least one of melatonin and vitamin C.
[0056] According to an embodiment of the present invention, exosomes derived from bone marrow mesenchymal stem cells can help the above substances penetrate the blood-brain barrier and enter the brain to exert the expected health care effect. Therefore, the above exosomes can reduce the dosage of substances that exert their effects in the brain and can be used to develop new delivery methods for health care products.
[0057] In some specific embodiments of the present invention, the medical device is nanoscale or micro-nanoscale, including but not limited to: at least one of: biomaterials for brain tissue engineering or regenerative medicine, brain tissue inductive implant devices, nanorobots, and micro-nanorobots.
[0058] According to an embodiment of the present invention, the particle size of the exosomes derived from bone marrow mesenchymal stem cells is about 40 to 150 nm, and can be used to carry smaller nanoscale medical devices to the brain to enable them to function better.
[0059] Use in the preparation of drugs, diagnostic reagents, health products or medical devices
[0060] The present invention proposes the use of stem cell-derived exosomes in the preparation of drugs, diagnostic reagents, health products or medical devices. According to an embodiment of the present invention, the drug is used to treat and / or prevent brain diseases, the diagnostic reagent is used to diagnose brain diseases, the health product is used to assist in improving memory or helping to improve sleep, and the application scenario of the medical device is the brain.
[0061] According to an embodiment of the present invention, the stem cells are derived from, including but not limited to, umbilical cord, bone marrow, embryo, placenta, fat, bone, cartilage, periodontium, synovium, muscle, lung, liver, and pancreas.
[0062] According to an embodiment of the present invention, the stem cells are mesenchymal stem cells.
[0063] According to an embodiment of the present invention, the stem cells include, but are not limited to, umbilical cord mesenchymal stem cells, bone marrow mesenchymal stem cells, adipose mesenchymal stem cells, dental pulp mesenchymal stem cells, placental mesenchymal stem cells, amniotic mesenchymal stem cells, synovial mesenchymal stem cells, and thymus mesenchymal stem cells. According to an embodiment of the present invention, the stem cells are derived from, but are not limited to, mice, rats, rabbits, dogs, pigs, and primates.
[0064] In some optional embodiments of the present invention, the primate is a non-human primate.
[0065] According to an embodiment of the present invention, the stem cells are mouse bone marrow mesenchymal stem cells.
[0066] According to an embodiment of the present invention, the brain is the cerebrum.
[0067] According to an embodiment of the present invention, the active pharmaceutical ingredient of the drug includes, but is not limited to, at least one of a compound, a polypeptide, a protein, a nucleic acid, and a polysaccharide.
[0068] In some specific embodiments of the present invention, the diagnostic reagent includes, but is not limited to, at least one of a biomarker, an antibody, an enzyme, a nucleic acid probe, and an imaging agent.
[0069] In some specific embodiments of the present invention, the substances used in the health care products to assist in improving memory include, but are not limited to, at least one of folic acid, DHA, calcium, magnesium, zinc, and vitamin B.
[0070] In some specific embodiments of the present invention, the active ingredients of the health care product that help improve sleep include, but are not limited to, at least one of melatonin and vitamin C.
[0071] In some specific embodiments of the present invention, the medical device is nanoscale or micro-nanoscale, including but not limited to: at least one of: biomaterials for brain tissue engineering or regenerative medicine, brain tissue inductive implant devices, nanorobots, and micro-nanorobots.
[0072] According to an embodiment of the present invention, the brain diseases include but are not limited to at least one of: Alzheimer's disease, Parkinson's disease, brain tumors, stroke, epilepsy, encephalitis, meningitis, Huntington's disease, amyotrophic lateral sclerosis, schizophrenia, depression, bipolar disorder, attention deficit hyperactivity disorder, autism spectrum disorder, migraine, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, and multiple sclerosis. Exosomes derived from bone marrow mesenchymal stem cells are brain-targeted and can be used as drug delivery carriers to deliver drugs that were previously difficult to reach brain tissue to the brain, increase the local concentration of drugs, and achieve effective treatment of brain diseases.
[0073] According to an embodiment of the present invention, the brain disease is Alzheimer's disease.
[0074] According to an embodiment of the present invention, the protein is IDE.
[0075] Those skilled in the art will appreciate that the features and advantages described above for the use of stem cell-derived exosomes in the preparation of brain-targeted vectors are also applicable to this use and will not be described in detail here.
[0076] Delivery System
[0077] The present invention proposes a delivery system. According to an embodiment of the present invention, it includes: a carrier, an active ingredient or a medical device; the carrier contains exosomes derived from stem cells, and the exosomes carry the active ingredient or the medical device; the delivery system delivers the active ingredient or the medical device to the brain. According to the delivery system described in the embodiment of the present invention, the active ingredient or the medical device is encapsulated inside and delivered to the brain through exosomes derived from stem cells, thereby achieving brain-targeted delivery, increasing or controlling the concentration of the active ingredient in the brain, enhancing the efficacy, and facilitating the medical device to work in brain application scenarios.
[0078] According to an embodiment of the present invention, the stem cells are derived from, including but not limited to, umbilical cord, bone marrow, embryo, placenta, fat, bone, cartilage, periodontium, synovium, muscle, lung, liver, and pancreas.
[0079] According to an embodiment of the present invention, the stem cells are mesenchymal stem cells.
[0080] According to an embodiment of the present invention, the stem cells include but are not limited to: umbilical cord mesenchymal stem cells, bone marrow mesenchymal stem cells, adipose mesenchymal stem cells, dental pulp mesenchymal stem cells, placental mesenchymal stem cells, amniotic mesenchymal stem cells, synovial mesenchymal stem cells, and thymus mesenchymal stem cells.
[0081] According to an embodiment of the present invention, the stem cells are derived from animals including but not limited to: mice, rats, rabbits, dogs, pigs, and primates.
[0082] In some optional embodiments of the present invention, the primate is a non-human primate.
[0083] According to an embodiment of the present invention, the stem cells are mouse bone marrow mesenchymal stem cells.
[0084] According to an embodiment of the present invention, the brain is the cerebrum.
[0085] According to an embodiment of the present invention, the active ingredients include but are not limited to: active pharmaceutical ingredients and other biological molecules.
[0086] In some specific embodiments of the present invention, the pharmaceutically active ingredient includes, but is not limited to, at least one of a compound, a polypeptide, a protein, a nucleic acid, and a polysaccharide.
[0087] The drug delivery system constructed according to the delivery system of the embodiment of the present invention can pass through the blood-brain barrier to deliver the active ingredients of the drug to the brain. Thus, brain-targeted drug delivery is achieved, the bioavailability of drugs for brain diseases is improved, the drug dosage is reduced, the side effects are reduced, and the prognosis of brain diseases is improved.
[0088] According to an embodiment of the present invention, the protein is IDE.
[0089] According to an embodiment of the present invention, the PDI of the IDE delivery system is 0.2-0.4, thereby further improving the consistency and brain targeting of IDE delivery.
[0090] According to an embodiment of the present invention, the other biological molecules include but are not limited to: at least one of a diagnostic reagent, a substance that assists in improving memory, and a substance that helps improve sleep.
[0091] In some specific embodiments of the present invention, the diagnostic reagent includes, but is not limited to, at least one of a biomarker, an antibody, an enzyme, a nucleic acid probe, and an imaging agent.
[0092] In some specific embodiments of the present invention, the substance that assists in improving memory includes, but is not limited to, at least one of folic acid, DHA, calcium, magnesium, zinc, and vitamin B.
[0093] In some specific embodiments of the present invention, the substance that helps improve sleep includes, but is not limited to, at least one of melatonin and vitamin C.
[0094] In some specific embodiments of the present invention, the medical device is nanoscale or micro-nanoscale, including but not limited to: at least one of: biomaterials for brain tissue engineering or regenerative medicine, brain tissue inductive implant devices, nanorobots, and micro-nanorobots.
[0095] It will be understood by those skilled in the art that the features and advantages described above for the use of stem cell-derived exosomes in the preparation of brain-targeted vectors are also applicable to this delivery system and will not be described in detail here.
[0096] use
[0097] The present invention proposes the use of the above-mentioned delivery system in the preparation of drugs, diagnostic reagents, health products or medical devices. According to an embodiment of the present invention, the drug is used to treat and / or prevent brain diseases, the diagnostic reagent is used to diagnose brain diseases, the health product is used to assist in improving memory or helping to improve sleep, and the application scenario of the medical device is the brain.
[0098] According to an embodiment of the present invention, the brain is the cerebrum.
[0099] Those skilled in the art will appreciate that the features and advantages described above for the delivery system are also applicable to this use and will not be described in detail here.
[0100] method
[0101] The present invention provides a method for preparing the aforementioned delivery system.
[0102] According to an embodiment of the present invention, the method comprises: mixing the exosomes with the active ingredient to obtain a mixture; and ultrasonically treating the mixture, thereby significantly improving the loading rate of the active ingredient.
[0103] In this article, the term "loading rate" refers to the loading efficiency of the target molecule in the exosome. The loading rate reflects the utilization efficiency of the carrier and the encapsulation efficiency of the target molecule.
[0104] According to an embodiment of the present invention, the active ingredient of the drug is IDE, and in the mixture, the mass particle number ratio of the IDE to the exosomes is greater than or equal to 1 μg: 2.5×10 10 Thus, the IDE load rate is further improved.
[0105] According to an embodiment of the present invention, the mass particle number ratio of the IDE to the exosome is (4-1) μg: 2.5×10 10 After a large number of experiments, the inventors determined the mass particle number ratio of the above IDE and exosomes. Within this parameter range, the IDE loading rate is relatively high.
[0106] According to an embodiment of the present invention, the protein concentration of the IDE is 1-100 μg / mL, and the particle concentration of the exosomes is 2.5×10 9 ~2.5×10 11 Pieces / mL.
[0107] In some preferred embodiments of the present invention, the mass particle number ratio of the IDE to the exosomes is 1 μg: 2.5×10 10 The protein concentration of the IDE was 1 μg / mL, and the particle concentration of the exosomes was 2.5×10 10 In the test animals, compared with direct nasal administration of IDE, the amount of IDE entering the brain by the EXO-IDE delivery system according to the embodiment of the present invention increased by 1.27 to 2.22 times.
[0108] According to an embodiment of the present invention, the active ingredient of the medicine is IDE, and the ultrasonic treatment time is not less than 30 minutes. The inventor has determined the above-mentioned preferred ultrasonic treatment time through a large number of experiments. Within this parameter range, the IDE loading rate is relatively high.
[0109] According to an embodiment of the present invention, the ultrasonic treatment time is 30 to 60 minutes, thereby further improving the drug loading rate.
[0110] According to an embodiment of the present invention, the power of the ultrasonic treatment is 90 kW and the temperature is 4° C. Thus, the drug loading rate is further improved.
[0111] In a specific embodiment of the present invention, the exosomes are obtained by the following method, comprising:
[0112] Bone marrow mesenchymal stem cells (derived from C57BL / 6 mice) were used for culture.
[0113] When the cells grow to 70-80% confluence, the MSC complete medium is replaced with a medium containing 10% exosome-free serum and cultured for 48 hours, and the cell culture supernatant is collected. When the cell culture reaches 70-80% confluence, they usually present a dense morphology, but have not yet fully formed a monolayer cell membrane. At this time, the MSC complete medium is replaced with a medium containing 10% exosome-free serum to obtain the aforementioned exosomes.
[0114] The cell culture supernatant is subjected to gradient centrifugation and ultrafiltration, including: the cell culture supernatant is subjected to gradient centrifugation at 300g for 10 minutes, 3000g for 25 minutes, and 10000g for 1 hour, and the supernatant after centrifugation is ultrafiltrated and concentrated (molecular weight cutoff is 100kDa) to obtain an exosome solution. Thus, cell debris, proteins and other larger cell products are removed by gradient centrifugation, and after ultrafiltration and concentration, the exosome solution has a higher working concentration, which is convenient for subsequent characterization, functional testing and application.
[0115] The scheme of the present invention will be explained below in conjunction with the embodiments. It will be appreciated by those skilled in the art that the following embodiments are only used to illustrate the present invention and should not be considered as limiting the scope of the present invention. Where specific techniques or conditions are not indicated in the embodiments, the techniques or conditions described in the literature in this area or the product specifications are used. The reagents or instruments used are not indicated by the manufacturer and are all conventional products that can be obtained commercially.
[0116] In the examples of the present invention, unless otherwise specified, the lysate is used to release insulin degrading enzyme (IDE) from exosomes so as to quantitatively detect the content of IDE using an enzyme-linked immunosorbent assay (ELISA) kit.
[0117] Example 1: Preparation of exosomes derived from mesenchymal stem cells
[0118] In this example, bone marrow mesenchymal stem cells (from mice C57BL / 6) were cultured. When the cells grew to 70-80% confluence, the MSC complete medium was replaced with a medium containing 10% exosome-free serum and cultured for 48 hours. The cell culture supernatant was collected and centrifuged at 300g for 10 minutes, 3000g for 25 minutes, and 10000g for 1 hour. After gradient centrifugation, the supernatant was ultrafiltrated and concentrated (molecular weight cutoff was 100kDa) to obtain a particle solution. The obtained particle solution was characterized by transmission electron microscopy and nanoparticle tracking analysis technology. The results are shown in FIG. Figure 1 shown.
[0119] The results showed that (1) the obtained particles were spherical vesicle-like structures, which were consistent with the extracellular vesicle structure of exosomes; (2) under the condition of 500-fold dilution, the particle concentration was 2.5×10 10 Particles / mL, with a particle size of 40-150nm, which is consistent with the particle size of exosomes.
[0120] The above results indicate that the particle solution obtained from the primary mouse bone marrow mesenchymal stem cell culture in this example is an exosome solution (hereinafter referred to as "EXO solution"), and the obtained particles have a vesicle-like structure with a particle size of 40 to 150 nm, and are exosomes derived from mesenchymal stem cells (hereinafter referred to as "EXO").
[0121] Example 2: Preparation of EXO-IDE drug system
[0122] In this example, IDE solution (1 μg / mL) and EXO solution (particle concentration of 2.5×10 10Particles / mL) were mixed in equal volumes, and IDE was loaded into EXO using two different treatment methods: electroporation and ultrasound. The loading efficiency of IDE by exosomes derived from mesenchymal stem cells was further investigated. The specific methods are as follows:
[0123] Electroporation: Use an electroporator and electroporate the mixed solution for 1 minute.
[0124] Extrusion method: Use a small liposome extruder to slowly and repeatedly extrude the mixed solution 5 times.
[0125] Ultrasonic method: The ultrasonic temperature is 4°C, the power is 90kw, and the time is 0.5 hour.
[0126] After the above different IDE drug loading methods were completed, each group of solutions was ultrafiltered and concentrated using an ultrafiltration centrifuge tube (molecular weight cutoff of 100 kDa) to remove free IDE and prepare the EXO-IDE drug system. Lysis solution was added to the EXO-IDE drug system (1% protease inhibitor mixture and 1% PMSF were added to the Biyuntian western blot lysate and placed at 4°C for 0.5 hours, and then the ELISA kit (Cloud-Clone Corp, Enzyme Linked Immunosorbent Assay for Insulin Degrading Enzyme) was used to detect the IDE loading amount and calculate the embedding rate.
[0127] The results are as follows Figure 2 shown.
[0128] The results showed that (1) when the EXO-IDE drug system was constructed by electroporation or extrusion, the loading rate of EXO on IDE was only about 40%; (2) beyond the inventors' expectations, when the EXO-IDE drug system was constructed by ultrasound, the loading rate of EXO on IDE was higher than 70%; compared with the electroporation and extrusion methods, the IDE loading rate was increased by 30%.
[0129] The above results show that the use of ultrasound to construct the EXO-IDE drug system makes EXO loading IDE more efficient.
[0130] Example 3: Optimization of experimental conditions for constructing EXO-IDE drug system using ultrasound
[0131] In this embodiment, the effect of ultrasound time on IDE load rate is first investigated. The specific method is as follows:
[0132] The IDE solution (1 μg / mL) and the EXO solution (particle concentration of 2.5×10 10The EXO-IDE drug system was prepared by mixing equal volumes of 1000 μg / mL of 1 ... Figure 3 (A) shown.
[0133] In this example, the effect of the volume ratio of IDE to EXO on the IDE loading rate was further investigated. The specific method is as follows:
[0134] Under the same ultrasonic conditions as in Example 2, namely, the ultrasonic temperature was 4°C, the power was 90 kW, and the time was 0.5 h. While maintaining the IDE solution (1 μg / mL) and the EXO solution (particle concentration was 2.5×10 10 When the total mixed volume of particles / mL) remains unchanged, different IDE and EXO feed volume ratios (2:1, 1:1, 0.5:1) were used to prepare the EXO-IDE drug system, detect the IDE loading amount, and calculate the embedding rate. The preparation method of the EXO-IDE drug system and the detection method of the IDE loading amount are the same as above. The results are shown in Figure 3 (B) shown.
[0135] The results showed that (1) there was no significant difference in the IDE embedding rate under the conditions of 0.5 hour and 1 hour of ultrasonic time, both of which were significantly better than 0 hour, and the ultrasonic time exceeding 0.5 hour did not increase the loading amount of IDE, so the ultrasonic time was controlled at 0.5 hour. (2) When the volume ratio of IDE to EXO was 2:1 and 1:1, there was no significant difference in the loading efficiency of IDE, both of which were close to 60%; while when the volume ratio of IDE to EXO was 0.5:1, the loading efficiency of IDE was less than 20%.
[0136] In summary, it is better to control the ultrasound time to 0.5 h, IDE (1 μg / mL) and EXO (particle concentration of 2.5×10 10 The feed volume ratio of particles / mL was controlled at 1:1.
[0137] Example 4: Physical and chemical characterization of EXO-IDE drug system
[0138] In this example, the EXO-IDE drug system was constructed by ultrasound method with reference to the preferred experimental conditions of Example 3, and its physicochemical characteristics were characterized. Specifically, the morphology and dispersibility were characterized by transmission electron microscopy, and the polydispersity coefficient and hydrodynamic diameter were detected by a particle size analyzer.
[0139] The results are as follows Figure 4 shown.
[0140] The results showed that (1) the transmission electron microscopy results showed that the constructed EXO-IDE drug system was still nanoscale in size and evenly distributed ( Figure 4 (A)); (2) The hydrodynamic diameter of the EXO-IDE drug system measured by the particle size analyzer was 153.05±14.25nm, and it still had a low polydispersity coefficient, PDI of 0.248 ( Figure 4 (B)).
[0141] The above results show that: (1) The EXO-IDE drug system of the present invention is nanoscale and has a small particle size, which makes it easier to penetrate biological barriers, such as the blood-brain barrier, which is particularly important for the treatment of brain diseases. (2) The EXO-IDE drug system is evenly distributed, which helps to protect the IDE drug from enzymatic hydrolysis in the body and improve the stability of the drug system. (3) The hydrodynamic diameter of the EXO-IDE drug system is 153.05±14.25nm, indicating that the particle size of the drug system is uniform and suitable for in vivo application, especially targeted delivery through the vascular system. (4) The EXO-IDE drug system has a low polydispersity coefficient, with a PDI of 0.248, which is much lower than 1, indicating that the particle size distribution is very concentrated, which helps to ensure the consistency and predictability of drug delivery.
[0142] Example 5: Investigation of brain targeting of EXO-IDE drug system
[0143] Based on the test results of Example 4, the inventors predicted that the EXO-IDE drug system of the present invention has brain targeting and verified it. The specific method is as follows:
[0144] IDE was labeled with Cy7 for tracing. IDE and IDE-Cy7 were subjected to the same experimental conditions as in Example 4, and IDE was loaded into EXO by ultrasound. 10 The feeding volume ratio of particles / mL was 1:1. After the ultrasonic treatment, ultrafiltration centrifugation was used for concentration to remove free IDE and IDE-Cy7, and the EXO-IDE-Cy7 drug system was prepared.
[0145] 8-month-old APP / PS1 transgenic mice (AD mice) with a genetic background of C57BL / 6J were selected and randomly divided into 3 groups, with 6 mice in each group. PBS, IDE-Cy7 and EXO-IDE-Cy7 drug systems were administered intranasally to APP / PS1 mice in each group, and the Cy7 fluorescence intensity in the mouse brain was detected by fluorescence imaging after 6 hours. Figure 5 shown.
[0146] The results showed that compared with simple nasal administration of IDE-Cy7, nasal administration of EXO-IDE-Cy7 could significantly increase the amount of IDE entering the brain ( Figure 5 (A)); Further fluorescence quantitative statistical analysis was performed on each experimental group. The results showed that compared with the IDE-Cy7 group, the brain entry of EXO-IDE-Cy7 was increased by 1.75 times, and the brain entry efficiency was significantly enhanced.
[0147] The above results show that the EXO-IDE drug system has significantly enhanced brain targeting, suggesting that mesenchymal stem cell-derived exosomes (MSC-EXO) can penetrate the blood-brain barrier.
[0148] It is expected that by enhancing brain targeting, MSC-EXO can more effectively deliver drugs to the brain, increase drug concentrations in the brain, and thus enhance therapeutic efficacy; enhanced brain targeting can also help reduce drug distribution to non-target tissues and improve treatment specificity; because it can penetrate the blood-brain barrier, MSC-EXO can also improve the bioavailability of brain disease drugs, reduce drug dosage, reduce sexual side effects, and help improve the prognosis of brain diseases. MSC-EXO can also be used as a carrier of diagnostic biomarkers for early diagnosis and monitoring of brain diseases.
[0149] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.
[0150] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations of the present invention. A person skilled in the art may change, modify, replace and vary the above embodiments within the scope of the present invention.
Claims
1. Use of stem cell-derived exosomes in the preparation of brain-targeted vectors for delivering active ingredients or medical devices to the brain.
2. The use according to claim 1, characterized in that The stem cells are derived from, but not limited to, umbilical cord, bone marrow, embryo, placenta, fat, bone, cartilage, periodontal, synovium, muscle, lung, liver, and pancreas; Optionally, the stem cells are mesenchymal stem cells; Optionally, the stem cells include, but are not limited to, umbilical cord mesenchymal stem cells, bone marrow mesenchymal stem cells, adipose mesenchymal stem cells, dental pulp mesenchymal stem cells, placental mesenchymal stem cells, amniotic mesenchymal stem cells, synovial mesenchymal stem cells, and thymus mesenchymal stem cells; Optionally, the stem cells are derived from, including but not limited to, mice, rats, rabbits, dogs, pigs, and primates; further, the stem cells are mouse bone marrow mesenchymal stem cells; Optionally, the brain is the cerebrum; Optionally, the active ingredients include, but are not limited to: pharmaceutical active ingredients, other biomolecules; Furthermore, the active pharmaceutical ingredient includes, but is not limited to: at least one of a compound, a polypeptide, a protein, a nucleic acid, and a polysaccharide; Furthermore, the protein is IDE; Further, the other biomolecules include, but are not limited to: at least one of a diagnostic agent, a substance that assists in improving memory, and a substance that helps improve sleep; Furthermore, the diagnostic reagent includes, but is not limited to, at least one of a biomarker, an antibody, an enzyme, a nucleic acid probe, and an imaging agent; Furthermore, the substance that assists in improving memory includes, but is not limited to: at least one of folic acid, DHA, calcium, magnesium, zinc, and vitamin B; Furthermore, the substance that helps improve sleep includes, but is not limited to: at least one of melatonin and vitamin C; Optionally, the medical device is nanoscale or micro-nanoscale, including but not limited to: at least one of biomaterials for brain tissue engineering or regenerative medicine, brain tissue inductive implant devices, nanorobots, and micro-nanorobots.
3. Use of stem cell-derived exosomes in the preparation of drugs, diagnostic reagents, health products or medical devices, wherein the drugs are used to treat and / or prevent brain diseases, the diagnostic reagents are used to diagnose brain diseases, the health products are used to assist in improving memory or helping to improve sleep, and the medical devices are used in the brain.
4. The use according to claim 3, characterized in that The stem cells are derived from, but not limited to, umbilical cord, bone marrow, embryo, placenta, fat, bone, cartilage, periodontal, synovium, muscle, lung, liver, and pancreas; Optionally, the stem cells are mesenchymal stem cells; Optionally, the stem cells include, but are not limited to, umbilical cord mesenchymal stem cells, bone marrow mesenchymal stem cells, adipose mesenchymal stem cells, dental pulp mesenchymal stem cells, placental mesenchymal stem cells, amniotic mesenchymal stem cells, synovial mesenchymal stem cells, and thymus mesenchymal stem cells; Optionally, the stem cells are derived from animals including but not limited to: mice, rats, rabbits, dogs, pigs, primates; Furthermore, the stem cells are mouse bone marrow mesenchymal stem cells; Optionally, the brain is the cerebrum; Optionally, the pharmaceutically active ingredient of the drug includes, but is not limited to, at least one of a compound, a polypeptide, a protein, a nucleic acid, and a polysaccharide; Optionally, the diagnostic agent includes, but is not limited to, at least one of a biomarker, an antibody, an enzyme, a nucleic acid probe, and an imaging agent; Optionally, the active ingredients of the health product for assisting in improving memory include, but are not limited to: at least one of folic acid, DHA, calcium, magnesium, zinc, and vitamin B; Optionally, the active ingredients of the health product that help improve sleep include, but are not limited to: at least one of melatonin and vitamin C; Optionally, the medical device is nanoscale or micro-nanoscale, including but not limited to: at least one of: biomaterials for brain tissue engineering or regenerative medicine, brain tissue inductive implant devices, nanorobots, and micro-nanorobots; Optionally, the brain disease includes, but is not limited to, at least one of: Alzheimer's disease, Parkinson's disease, brain tumor, stroke, epilepsy, encephalitis, meningitis, Huntington's disease, amyotrophic lateral sclerosis, schizophrenia, depression, bipolar disorder, attention deficit hyperactivity disorder, autism spectrum disorder, migraine, Creutzfeldt-Jakob disease, normal pressure hydrocephalus, and multiple sclerosis; Further, the brain disease is Alzheimer's disease; Furthermore, the protein is IDE.
5. A delivery system, characterized in that include: carrier, active ingredient or medical device; The carrier comprises exosomes derived from stem cells, and the exosomes carry the active ingredient or medical device; The delivery system delivers the active ingredient or medical device to the brain.
6. The delivery system according to claim 5, characterized in that The stem cells are derived from, but not limited to, umbilical cord, bone marrow, embryo, placenta, fat, bone, cartilage, periodontal, synovium, muscle, lung, liver, and pancreas; Optionally, the stem cells are mesenchymal stem cells; Optionally, the stem cells include, but are not limited to, umbilical cord mesenchymal stem cells, bone marrow mesenchymal stem cells, adipose mesenchymal stem cells, dental pulp mesenchymal stem cells, placental mesenchymal stem cells, amniotic mesenchymal stem cells, synovial mesenchymal stem cells, and thymus mesenchymal stem cells; Optionally, the stem cells are derived from animals including but not limited to: mice, rats, rabbits, dogs, pigs, primates; Furthermore, the stem cells are mouse bone marrow mesenchymal stem cells; Optionally, the brain is the cerebrum; Optionally, the active ingredients include, but are not limited to: pharmaceutical active ingredients, other biomolecules; Furthermore, the active pharmaceutical ingredient includes, but is not limited to: at least one of a compound, a polypeptide, a protein, a nucleic acid, and a polysaccharide; Furthermore, the protein is IDE; Further, the PDI of the IDE delivery system is 0.2 to 0.4; Further, the other biomolecules include, but are not limited to: at least one of a diagnostic agent, a substance that assists in improving memory, and a substance that helps improve sleep; Furthermore, the diagnostic reagent includes, but is not limited to, at least one of a biomarker, an antibody, an enzyme, a nucleic acid probe, and an imaging agent; Furthermore, the substance that assists in improving memory includes, but is not limited to: at least one of folic acid, DHA, calcium, magnesium, zinc, and vitamin B; Furthermore, the substance that helps improve sleep includes, but is not limited to: at least one of melatonin and vitamin C; Optionally, the medical device is nanoscale or micro-nanoscale, including but not limited to: at least one of biomaterials for brain tissue engineering or regenerative medicine, brain tissue inductive implant devices, nanorobots, and micro-nanorobots.
7. Use of the delivery system according to claim 5 or 6 in the preparation of a drug, a diagnostic reagent, a health product or a medical device, wherein the drug is used to treat and / or prevent brain diseases, the diagnostic reagent is used to diagnose brain diseases, the health product is used to assist in improving memory or helping to improve sleep, and the application scenario of the medical device is the brain; Optionally, the brain is the cerebrum.
8. A method for preparing the delivery system of claim 5 or 6.
9. The method according to claim 8, characterized in that include: Mixing the exosomes with the active ingredient to obtain a mixture; The mixture was sonicated.
10. The method according to claim 8, characterized in that The active ingredient of the drug is IDE, and in the mixture, the mass particle number ratio of the IDE to the exosomes is greater than or equal to 1 μg: 2.5×10 10 indivual; Furthermore, the mass particle number ratio of the IDE to the exosomes is (4-1) μg: 2.5×10 10 indivual; Furthermore, the protein concentration of the IDE is 1-100 μg / mL, and the particle concentration of the exosomes is 2.5×10 9 ~2.5×10 11 Pieces / mL; Optionally, the active pharmaceutical ingredient is IDE, and the ultrasonic treatment time is not less than 30 min; Furthermore, the ultrasonic treatment time is 30 to 60 minutes; Furthermore, the power of the ultrasonic treatment is 90kw and the temperature is 4°C.
Citation Information
Patent Citations
Three-dimensionally cultured mesenchymal stem cells derived exosomes and preparation method and application thereof
CN109913409A
Brain-targeting exosome and preparing method and application thereof
CN110115769A
Exosome delivery carrier as well as preparation method and application thereof
CN114081965A
Preparation method and application of drug-loaded brain-targeting exosome
CN115177742A
